Eramet

Much weaker, as expected… and rather uninspiring in the short-term (H124).

23/02/24 -"There were no real surprises in the FY23 results. Market conditions were tough, with depressed prices across the board. The H124 will remain weak (lower than H123) but the group hopes for a better ..."

PDF page sample
Pages
85
Language
English
Published on
23/02/24
Download
You may also be interested by these reports :
06/11/26
Aperam’s Q326 results are slightly below consensus but broadly in line with previous guidance, with EBITDA reaching €103m. Despite weak European ...
06/11/26
Outokumpu’s Q326 results were broadly in line with expectations, with sales up 19.8% to €1,555m and adjusted EBITDA of €101m. However, the outlook is ...
05/11/26
ArcelorMittal’s Q326 results were broadly in line with expectations, with EBITDA up 34.1% yoy to US$2.0bn and margin reaching 12.3%. A US$1.1bn ...
05/11/26
Tenaris delivered strong Q326 results, beating consensus, particularly at the EBITDA and EBIT levels, with sales of US$3.1bn and net income up 15% ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO